Global control of hepatitis C: where challenge meets opportunity
|
journal
|
July 2013 |
The global burden of hepatitis C
|
journal
|
January 2009 |
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
|
journal
|
July 2013 |
Future hepatitis C virus treatment: interferon-sparing combinations: Future IFN-free HCV treatment
|
journal
|
January 2011 |
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
|
journal
|
April 2014 |
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|
journal
|
May 2014 |
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
|
journal
|
September 2012 |
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
|
journal
|
January 2012 |
A Quantitative High-Resolution Genetic Profile Rapidly Identifies Sequence Determinants of Hepatitis C Viral Fitness and Drug Sensitivity
|
journal
|
April 2014 |
Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals
|
journal
|
June 2011 |
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus
|
journal
|
April 2011 |
Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate
|
journal
|
August 2012 |
Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance
|
journal
|
December 2011 |
Genetic diversity and evolution of hepatitis C virus - 15 years on
|
journal
|
November 2004 |
The Epidemic Behavior of the Hepatitis C Virus
|
journal
|
June 2001 |
Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review
|
journal
|
May 2013 |
Relationship Between Adherence to Hepatitis C Virus Therapy and Virologic Outcomes: A Cohort Study
|
journal
|
September 2011 |
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
|
journal
|
February 2010 |
Factors influencing adherence in Hepatitis-C infected patients: a systematic review
|
journal
|
April 2014 |
Expanding Access to Treatment for Hepatitis C in Resource-Limited Settings: Lessons From HIV/AIDS
|
journal
|
March 2012 |
Evolutionary Dynamics of Complex Networks of HIV Drug-Resistant Strains: The Case of San Francisco
|
journal
|
January 2010 |
Hospital and Societal Costs of Antimicrobial‐Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship
|
journal
|
October 2009 |
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS
|
journal
|
January 2001 |
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
|
journal
|
July 2000 |
Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin
|
journal
|
May 2013 |
Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence
|
journal
|
February 2013 |
Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research
|
journal
|
July 2009 |
Mixing the right hepatitis C inhibitor cocktail
|
journal
|
January 2011 |
The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America
|
journal
|
January 2008 |
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome
|
journal
|
September 2012 |
Adherence and drug resistance: predictions for therapy outcome
|
journal
|
April 2000 |
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
|
journal
|
April 2008 |
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
|
journal
|
April 2013 |
Production of resistant HIV mutants during antiretroviral therapy
|
journal
|
July 2000 |
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
|
journal
|
May 2010 |
Intergenerational Phenotypic Mixing in Viral Evolution
|
journal
|
February 2013 |
Influence of Viral Replication Mechanisms on Within-Host Evolutionary Dynamics: Influence of Viral Replication Mechanisms on Within-Host Evolutionary Dynamics
|
journal
|
June 2012 |
Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics
|
journal
|
December 2012 |
Assessing and achieving readiness to initiate HIV medication
|
journal
|
July 2006 |
Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1
|
journal
|
June 2014 |
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
|
journal
|
April 2013 |
Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration
|
journal
|
October 2013 |
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
|
journal
|
December 2011 |
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
|
journal
|
June 2010 |
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
|
journal
|
December 2011 |
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
|
journal
|
May 2014 |
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy
|
journal
|
October 1998 |
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics
|
journal
|
October 2014 |
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration
|
journal
|
May 2011 |
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
|
journal
|
May 2010 |
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
|
journal
|
February 2013 |
Effects of Computerized Clinical Decision Support Systems on Practitioner Performance and Patient Outcomes: A Systematic Review
|
journal
|
March 2005 |
Mathematical Analysis of HIV-1 Dynamics in Vivo
|
journal
|
January 1999 |
Evolutionary Analysis of Human Immunodeficiency Virus Type 1 Therapies Based on Conditionally Replicating Vectors
|
journal
|
October 2012 |
Safety, Tolerability and Pharmacokinetics of Yimitasvir Phosphate Capsule, a Novel Oral Hepatitis C Virus NS5A Inhibitor, in Healthy Chinese Volunteers
|
journal
|
May 2019 |
HCV cirrhosis at the edge of decompensation: Will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?
|
journal
|
December 2014 |
The price of innovation: new estimates of drug development costs
|
journal
|
March 2003 |
Population biological principles of drug-resistance evolution in infectious diseases
|
journal
|
March 2011 |
NS5A inhibitors to treat hepatitis C virus infection
|
journal
|
September 2012 |
A New Era of Hepatitis C Treatment
|
journal
|
July 2012 |
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
|
journal
|
April 2014 |
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
|
journal
|
May 2014 |
Curing Chronic Hepatitis C — The Arc of a Medical Triumph
|
journal
|
April 2014 |
HIV therapy: Managing resistance
|
journal
|
July 2000 |
Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment
|
journal
|
July 2014 |